36.54
+0.09000092(+0.25%)
Currency In USD
| Previous Close | 36.45 |
| Open | 36.25 |
| Day High | 37.25 |
| Day Low | 36.25 |
| 52-Week High | 50 |
| 52-Week Low | 25.81 |
| Volume | 1.13M |
| Average Volume | 1.48M |
| Market Cap | 3.52B |
| PE | -6.16 |
| EPS | -5.93 |
| Moving Average 50 Days | 32.47 |
| Moving Average 200 Days | 33.97 |
| Change | 0.09 |
If you invested $1000 in Ultragenyx Pharmaceutical Inc. (RARE) 10 years ago, it would be worth $364.38 as of December 04, 2025 at a share price of $36.54. Whereas If you bought $1000 worth of Ultragenyx Pharmaceutical Inc. (RARE) shares 5 years ago, it would be worth $284.29 as of December 04, 2025 at a share price of $36.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences
GlobeNewswire Inc.
Nov 04, 2025 9:01 PM GMT
Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55 times the purchase price Proceeds to fund four expec
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups
GlobeNewswire Inc.
Oct 30, 2025 12:00 PM GMT
NOVATO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the first patient has been dosed in the Aurora study (NCT07157254) evaluating the efficacy and safety of GTX-102 (apazunersen), an
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
GlobeNewswire Inc.
Oct 28, 2025 8:30 PM GMT
NOVATO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today